Market Place
Sourcing Support
All News #Library
Rare Diseases
JCR Pharma Unveils Investigational Lysosomal Disorder Treatments
04 Feb 2026 //
BUSINESSWIRE
Italfarmaco, JCR Pharma Partner On Givinostat Commercialization
24 Dec 2025 //
BUSINESSWIRE
JCR Pharmaceuticals Announces Licensing Agreement with Menagen
01 Oct 2025 //
BUSINESSWIRE
Japan Grants Orphan Drug Designation to JR-446 for MPS IIIB
29 Sep 2025 //
BUSINESSWIRE
JCR Pharma & Alexion Hit Milestone in Neurodegenerative Program
19 Sep 2025 //
PHARMAWEB
JCR Pharma Shares Pabinafusp Alfa`s Data for MPS II at ICIEM
08 Sep 2025 //
PHARMAWEB
Medipal Holdings, JCR Pharmaceuticals Ink Global Licensing Deal
02 Sep 2025 //
PHARMAWEB
Orphan Drug Designation for JR-446 for MPS Type IIIB by EC
24 Jun 2025 //
BUSINESSWIRE
JCR Pharmaceuticals Launches MPS Type II Disease Awareness Film
18 Jun 2025 //
BUSINESSWIRE
JR-446 Designated Orphan Drug for MPS IIIB by FDA
07 May 2025 //
BUSINESSWIRE
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo
19 Mar 2024 //
BUSINESSWIRE
JCR Pharmaceuticals Celebrates Rare Disease Day 2024
29 Feb 2024 //
BUSINESSWIRE
U.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of MPS IIIA
15 Dec 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.